A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma

The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index

Fay J. Hlubocky*, Kimberly A Webster, Jennifer Beaumont, John Cashy, Diane Paul, Amy Abernethy, Karen L. Syrjala, Jamie Von Roenn, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.

Original languageEnglish (US)
Pages (from-to)1942-1946
Number of pages5
JournalLeukemia and Lymphoma
Volume54
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Symptom Assessment
Lymphoma
Quality of Life
Neoplasms
Therapeutics
Reproducibility of Results
Chronic Disease
Clinical Trials
Psychology
Research

Keywords

  • FLymSI-18
  • HRQOL
  • Lymphoma
  • Symptom Index

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{076c0e3e916d4f66a9c8a1f23a015d48,
title = "A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index",
abstract = "Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.",
keywords = "FLymSI-18, HRQOL, Lymphoma, Symptom Index",
author = "Hlubocky, {Fay J.} and Webster, {Kimberly A} and Jennifer Beaumont and John Cashy and Diane Paul and Amy Abernethy and Syrjala, {Karen L.} and {Von Roenn}, Jamie and David Cella",
year = "2013",
month = "9",
day = "1",
doi = "10.3109/10428194.2012.762977",
language = "English (US)",
volume = "54",
pages = "1942--1946",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma : The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. / Hlubocky, Fay J.; Webster, Kimberly A; Beaumont, Jennifer; Cashy, John; Paul, Diane; Abernethy, Amy; Syrjala, Karen L.; Von Roenn, Jamie; Cella, David.

In: Leukemia and Lymphoma, Vol. 54, No. 9, 01.09.2013, p. 1942-1946.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma

T2 - The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index

AU - Hlubocky, Fay J.

AU - Webster, Kimberly A

AU - Beaumont, Jennifer

AU - Cashy, John

AU - Paul, Diane

AU - Abernethy, Amy

AU - Syrjala, Karen L.

AU - Von Roenn, Jamie

AU - Cella, David

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.

AB - Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.

KW - FLymSI-18

KW - HRQOL

KW - Lymphoma

KW - Symptom Index

UR - http://www.scopus.com/inward/record.url?scp=84882985462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882985462&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.762977

DO - 10.3109/10428194.2012.762977

M3 - Article

VL - 54

SP - 1942

EP - 1946

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -